Article Figures & Data
Figures
- Figure 1.
Progression-free (A) and overall (B) survival from treatment initiation according to Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation status of patients treated with pemetrexed/docetaxel in second or third line.
- Figure 2.
Progression-free (A) and overall (B) survival from treatment initiation according to Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation of patients treated with pemetrexed/docetaxel in second or third line.
Tables
In this issue
Jump to section
Related Articles
Cited By...
- Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment
- The likelihood of heterogeneity or additional mutation in KRAS or associated oncogenes to compromise targeting of oncogenic KRAS G12C
- EGFR-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline EGFR T790M Testing
- Epidermal growth factor receptor mutations should be considered as a prognostic factor for survival of patients with pathological fractures or painful bone metastases from non-small cell lung cancer